1. Introduction {#sec1-ijms-20-04757}
===============

Alzheimer's disease (AD) is one of the most common neurodegenerative disorders, which accounts for up to 75% of all dementia cases \[[@B1-ijms-20-04757],[@B2-ijms-20-04757]\]. AD can be categorized into two major types: Early-onset AD (EOAD) and late-onset AD (LOAD). EOAD is usually inherited autosomal dominantly, and occurs before the age of 60--65 years. Presenilin-1 (*PSEN1*; MIM \#104311) \[[@B3-ijms-20-04757]\], presenilin-2 (*PSEN2*; MIM \#600759) \[[@B4-ijms-20-04757]\], and amyloid protein precursor (*APP*; MIM \#104760) gene mutations \[[@B5-ijms-20-04757],[@B6-ijms-20-04757]\] and duplications \[[@B7-ijms-20-04757]\] can cause autosomal-dominant EOAD. Mutations in these genes have been relatively rarely observed \[[@B8-ijms-20-04757],[@B9-ijms-20-04757],[@B10-ijms-20-04757],[@B11-ijms-20-04757],[@B12-ijms-20-04757]\], since the prevalence is estimated to be 5.3 per 100,000 individuals \[[@B13-ijms-20-04757]\]. The significance of *APP*, *PSEN1,* and *PSEN2* in AD were confirmed by different genetic studies, and majority of these mutations share a common feature of exhibiting increased production of the Aβ1-42 peptide, associated with altered gamma secretase activity \[[@B5-ijms-20-04757],[@B14-ijms-20-04757]\]. Among these three genes, *PSEN1* mutations were more frequently observed in AD, since approximately 252 different mutations were reported (<http://www.alzforum.org/mutations>, accessed in June 2019). Mutations in *APP* and *PSEN2* were less frequently observed, since only 35 pathogenic *APP* mutations and 20 pathogenic *PSEN2* mutations have been reported (<http://www.alzforum.org/mutations>, accessed in June 2019).

Despite the fact that genomic sequencing and bioinformatics have dramatically improved the identification of other genetic risk factors over the last few years, the interpretation of rare variants remains a challenge \[[@B1-ijms-20-04757],[@B2-ijms-20-04757],[@B8-ijms-20-04757],[@B10-ijms-20-04757],[@B15-ijms-20-04757],[@B16-ijms-20-04757]\]. Remarkably, the age of onset and disease progression is not only influenced by genetics, but also by both lifestyle and environmental factors \[[@B17-ijms-20-04757],[@B18-ijms-20-04757],[@B19-ijms-20-04757],[@B20-ijms-20-04757],[@B21-ijms-20-04757]\]. These factors may cause altered gene expression by epigenetic modifications, thereby affecting AD pathology \[[@B1-ijms-20-04757],[@B17-ijms-20-04757],[@B19-ijms-20-04757],[@B22-ijms-20-04757]\]. Although majority of these mutations of these three genes are associated with familial EOAD, follow the Mendelian rules, several de novo cases of AD have been reported in patients without any family history of dementia \[[@B10-ijms-20-04757],[@B23-ijms-20-04757]\].

The fastest increase in the number of elderly individuals has been observed in the East Asian countries. Approximately 60% of all patients diagnosed with dementia inhabit the Asian countries \[[@B24-ijms-20-04757]\]. However, the genetics of EOAD are not well characterized, since only a few reports are available regarding mutations in EOAD causative genes ([Figure 1](#ijms-20-04757-f001){ref-type="fig"}) \[[@B25-ijms-20-04757],[@B26-ijms-20-04757],[@B27-ijms-20-04757],[@B28-ijms-20-04757],[@B29-ijms-20-04757],[@B30-ijms-20-04757],[@B31-ijms-20-04757],[@B32-ijms-20-04757],[@B33-ijms-20-04757],[@B34-ijms-20-04757],[@B35-ijms-20-04757],[@B36-ijms-20-04757],[@B37-ijms-20-04757],[@B38-ijms-20-04757],[@B39-ijms-20-04757],[@B40-ijms-20-04757],[@B41-ijms-20-04757],[@B42-ijms-20-04757],[@B43-ijms-20-04757],[@B44-ijms-20-04757]\]. Therefore, the aim of the present study was to report mutations in additional cases, including sporadic ones, since our last update from 2009 for Asian patients with EOAD. We performed a genetic screening for mutations in the *PSEN1*, *PSEN2*, and *APP* genes in 200 patients with EOAD.

2. Results {#sec2-ijms-20-04757}
==========

2.1. Identified Gene Mutations of APP {#sec2dot1-ijms-20-04757}
-------------------------------------

Considering that the genetic background of EOAD in the Asian population is not well characterized \[[@B10-ijms-20-04757],[@B15-ijms-20-04757]\], we reported non-synonymous mutations in 200 clinically diagnosed patients with EOAD across four Asian countries, including Thailand, Malaysia, the Philippines, and Korea between 2009 and 2018. A total of 32 mutation carriers, including affected relatives in EOAD families and sporadic cases, were found among the 200 patients. From the 21 novel and known non-synonymous variants, five *APP* variants were found in Korean patients, and one *APP* variant was identified in a Thai patient. Nine, two, and one *PSEN1* variant was identified in Korean patients, Malaysian siblings, and a Thai patient, respectively. Unlike *PSEN1* mutations, *PSEN2* mutations were a rare in EOAD, with only three variants identified in Korean patients ([Table 1](#ijms-20-04757-t001){ref-type="table"}). Moreover, the mutation spectrum associated with AD for all Asian countries is shown in [Table 2](#ijms-20-04757-t002){ref-type="table"} \[[@B29-ijms-20-04757],[@B31-ijms-20-04757],[@B32-ijms-20-04757],[@B45-ijms-20-04757],[@B46-ijms-20-04757],[@B47-ijms-20-04757],[@B48-ijms-20-04757],[@B49-ijms-20-04757],[@B50-ijms-20-04757],[@B51-ijms-20-04757],[@B52-ijms-20-04757],[@B53-ijms-20-04757]\].

Six novel *APP* mutations were found in six out of 200 EOAD patients ([Table 1](#ijms-20-04757-t001){ref-type="table"}). A novel mutation, c.2005G \> C, p.(Val669Leu) substitution, present in a 56-year-old Korean female and two of her daughters \[[@B67-ijms-20-04757]\]. The clinical features were typical of AD with aggravated diffuse brain atrophy and a small vessel ischemic lesion. The c.1810C \> T, p.(Val604Met) mutation was found in a Thai patient with EOAD \[[@B12-ijms-20-04757]\]. The patient was diagnosed in 2013 with AD presenting logopenic aphasia, and this variant appeared to be associated with the phenotype \[[@B12-ijms-20-04757]\]. Three *APP* variants---c.674T \> C (p.Val225Ala); c.1450C \> T, (p.Pro484Ser); and c.890C \> T, (p.Thr297Met)---were found in Korean patients with EOAD at an onset age between 60 and 65 years. Although these three variants have not been previously reported in the literature, their allele frequencies in the ExAC database are 0.00002471, 0.00003304, and 0.0002062, respectively. Only one novel *APP* mutation---c.1810C \> T p.(Val604Met)---was identified during this screen in a Thai patient with EOAD; this mutation is presumed to be associated with altered *APP* function due to increased hydrophobicity of methionine in the helix \[[@B12-ijms-20-04757]\]. Over 35 *APP* variants have been discovered in exons 16 and 17; of them, 10 have been reported in Asia ([Table 2](#ijms-20-04757-t002){ref-type="table"}, [Figure 2](#ijms-20-04757-f002){ref-type="fig"}a). Remarkably, a novel mutation in the *APP* gene, Val669Leu, was discovered in a Korean female patient with AD \[[@B67-ijms-20-04757]\]. She developed cognitive decline at the age of 56 years, and MRI scans showed mild global atrophy with medial temporal lobe predominance and hippocampal atrophy. The patient may have a positive history of the disease, since her mother was also diagnosed. APP V669L was predicted as the non-damaging variant by the PolyPhen2 and Sorting Intolerant From Tolerant (SIFT) tools. *APP* mutations are rare in Korean populations because of the presence of only one mutation in *APP*, V715M (V715M). APP V669L is located near the β-secretase cleavage site, adjacent to the Swedish *APP* (KM670/671NL) mutation ([Figure 2](#ijms-20-04757-f002){ref-type="fig"}b) \[[@B68-ijms-20-04757]\]. This mutation may disrupt amyloid-beta metabolism.

2.2. Identified Gene Mutations of PSEN1 {#sec2dot2-ijms-20-04757}
---------------------------------------

Twelve *PSEN1* mutations were identified in 20 patients with EOAD ([Table 1](#ijms-20-04757-t001){ref-type="table"}). Remarkably, a previously reported *PSEN1* mutation---Val96Phe---was identified in two siblings from Malaysia. This mutation was reported previously in a Japanese family with disease onset in the late 40s or 50s \[[@B32-ijms-20-04757]\]. Similar to Japanese patients, the disease onset in these siblings was in the 40s, and they presented symptomatic changes in behavior and personality, such as apathy and withdrawal. In addition, seven additional novel or known *PSEN1* mutations, including Thr116Ile, Thr119Ile His163Pro, Leu226Phe, Gly209Ala, Leu232Pro \[[@B69-ijms-20-04757]\], and Gly417Ala \[[@B11-ijms-20-04757]\], have been identified in Korean patients with AD. Importantly, even though *PSEN1* is the most commonly involved gene, with \> 231 mutations reported as pathogenic in the Alzforum database ([www.alzforum.org/mutations](www.alzforum.org/mutations)), this study did not find any *PSEN1* mutation in the Thai and Philippine cohorts. Moreover, only three Malaysian patients with AD have been identified to carry a novel mutation, Glu280Lys \[[@B70-ijms-20-04757]\]. As Korea is one of the fastest "aging countries" in the world, the number of AD, including EOAD, patients will rapidly increase \[[@B24-ijms-20-04757]\]. The carriers of *PSEN1* mutation presented with isolated and progressive cognitive decline. Another patient carrying the *PSEN1* p.Gly417Ala substitution also exhibited an atypical presentation: Cerebellar ataxia and extra pyramidal with pessimism syndrome. According to the Alzheimer's Research Forum database, more than 230 *PSEN1* variants have been identified worldwide ([www.alzforum.org/mutations](www.alzforum.org/mutations)). Among them, \> 55 variants have been identified in Japan, Korea, the People's Republic of China, Malaysia, and Thailand ([Figure 3](#ijms-20-04757-f003){ref-type="fig"}).

2.3. Identified Gene Mutations of PSEN2 {#sec2dot3-ijms-20-04757}
---------------------------------------

We also discovered the following three *PSEN2* mutations in Korean patients for the first time: Arg62Cys, His169Asn \[[@B9-ijms-20-04757]\], and Val214Leu. Arg62Cys (CGC TGC) was discovered in the Asian population for the first time by our research group. The mutation was identified in a patient with dementia. Memory impairment, personality change, and disorientation appeared at the age of 49 years. Val214Leu was one of the first *PSEN2* mutations identified in an Asian population. In addition, it is the first mutation identified in the TM-IV region of *PSEN2*. Val214Leu mutation was identified in the following two unrelated patients: A 70-year-old patient with AD-type dementia and a 56-year-old patient with memory impairment. The exact family history is unknown for both patients. A pathogenic mutation p.His169Asn in the *PSEN2* gene in a Korean patient with EOAD has also been identified \[[@B9-ijms-20-04757]\]. PolyPhen-2 and SIFT software analyses predicted this mutation to be a probable damaging variant. The mutation was identified in a 58-year-old woman who was presented with progressive memory decline in her 50s. The patient had an apolipoprotein E genotype (APOE) ε 3/3 polymorphism. The family history of the proband generations was negative for any neurological disease, indicative of a de novo case of AD. All living family members declined genetic testing. Interestingly, *PSEN2* p.His169Asn mutation was previously identified in one patient with familial LOAD and one patient with sporadic frontotemporal dementia (FTD) from People's Republic of China \[[@B40-ijms-20-04757]\]; however, the pathogenic nature has not been clarified yet. Compared with the two Chinese patients, the Korean patient showed similar clinical manifestation with the proband with frontal variant AD. Although no additional mutation was reported at residue 169 of the PSEN2 protein, the p.His169Asn mutation was found in the conserved TM-III region of *PSEN2*, containing the pathogenic variants (p.M174V and p.S175C), based on the algorithms to predict the pathogenicity of the mutations described by Guerreiro et al. \[[@B71-ijms-20-04757]\] More than 40 missense and frameshift mutations in the *PSEN2* gene have been reported so far; however, until 2019, no pathogenic mutation has been found in *PSEN2* in any Asian country. The findings of this study as well as those of recent studies revealed novel and known *PSEN2* variants in Korean and Chinese patients ([Figure 4](#ijms-20-04757-f004){ref-type="fig"}).

3. Discussion {#sec3-ijms-20-04757}
=============

In this study, we performed genetic screening for mutations in the *APP*, *PSEN1*, and *PSEN2* genes in 200 clinically diagnosed EOAD patients across four Asian countries, including Thailand, Malaysia, the Philippines, and Korea from 2009 to 2018, and identified 21 novel and known missense mutations. According to Guerreiro's algorithm \[[@B71-ijms-20-04757]\], pathogenicity was considered as "definite" for two *APP*, "probable" for nine *PSEN1*, and "possible" for three *PSEN2* mutations. The pathological effect of the known mutations deserves discussion because of incomplete penetrance, nonpathogenicity, or a wide range of age onset \[[@B41-ijms-20-04757],[@B47-ijms-20-04757],[@B52-ijms-20-04757],[@B56-ijms-20-04757],[@B57-ijms-20-04757],[@B58-ijms-20-04757],[@B59-ijms-20-04757],[@B60-ijms-20-04757],[@B61-ijms-20-04757],[@B63-ijms-20-04757],[@B64-ijms-20-04757],[@B65-ijms-20-04757]\].

This study detected six mutations in *APP,* among patients under 65 years of age. Among them, only one *APP*, the Val669Leu mutation, was located in the amyloid processing area. The patient with APP Val669Leu presented had a progressive short-term memory impairment, as observed in typical AD. However, atypical symptoms of AD, including focal signs and symptoms, were also observed. Frontal lobe impairment (depression, apathy, and disinhibition), epileptic seizures, and myoclonus were also observed. As *APP* is responsible for the disease it is located relatively near to the beta secretase cleavage site; therefore, Val669Leu may interfere with the normal proteolytic processing of APP. This mechanism is thought to involve alternative proteolytic processing pathways \[[@B5-ijms-20-04757],[@B6-ijms-20-04757],[@B7-ijms-20-04757],[@B47-ijms-20-04757],[@B72-ijms-20-04757]\].

*PSEN1* c.286G \> T, p.(Val96Phe) substitution was identified in two siblings from Malaysia. This was the second report of the *PSEN1* Val96Phe mutation among EOAD patients in Asia. Patients presented similar phenotypes like the previously described Japanese patients: The disease onset was in their 40s, and they presented a symptomatic change in behavior and personality, such as apathy and withdrawal. *PSEN1* Val96Phe mutation is considered pathogenic and can lead to an increase in Aβ42 level and Aβ42/Aβ40 ratio in cell cultures \[[@B32-ijms-20-04757]\]. These findings suggest that mutations in TM-I may be responsible for pathogenic mutations in EOAD. Cellular studies with different mutations (including Val96Phe) suggest that TM-I plays a significant role in APP trafficking and amyloid peptide cleavage. Therefore, we speculate about an underestimation of its frequency. In addition, two *PSEN1* mutations---Trp165Cys \[[@B73-ijms-20-04757]\] and p.Ala285Val---were identified in a 53-year-old male who presented memory decline, followed by disorientation, and in a 46-year-old woman who presented with progressive memory dysfunction, respectively. Both patients had probable EOAD, and the family history was positive in them. Both mutations were previously shown to have increased Aβ42 and decreased Aβ40 levels. Moreover, both mutations could elevate the Aβ42/Aβ40 ratio by impairing the gamma secretase functions \[[@B49-ijms-20-04757],[@B59-ijms-20-04757],[@B72-ijms-20-04757],[@B74-ijms-20-04757],[@B75-ijms-20-04757],[@B76-ijms-20-04757]\].

Similar to *APP* and *PSEN1* mutations, *PSEN2* mutations can also enhance Aβ production and contribute to AD development. An extensive literature search for *PSEN2* mutations was conducted. Thirty-eight *PSEN2* mutations have been reported yet, and most of these mutations were identified in European and African populations. Until now, only five missense mutations have been reported in Asian populations. Asn141Tyr was identified in a Chinese Han patient with EOAD \[[@B77-ijms-20-04757]\], Gly34Ser was found in a Japanese patient \[[@B4-ijms-20-04757]\], and three possibly pathogenic mutations---Arg62Cys, Val214Leu, and His169Asn---were reported in this study. *PSEN2* mutations are associated with variable penetrance and a wide age range of disease onset, from 45 to 88 years \[[@B78-ijms-20-04757],[@B79-ijms-20-04757]\]. PSEN2 is a transmembrane protein and a component of γ-secretase intramembrane protease, and is involved in various signaling pathways in AD development \[[@B80-ijms-20-04757],[@B81-ijms-20-04757]\].

In an EOAD patient cohort, the estimated mutation frequencies for the three genes were \< 1% for *APP*, 6% for *PSEN1*, and 1% for *PSEN2* \[[@B82-ijms-20-04757]\]. Together, they explain only 5% to 10% of the mutational profile in patients with EOAD \[[@B82-ijms-20-04757],[@B83-ijms-20-04757]\]; however, approximately 90% of the mutations remain genetically unexplained \[[@B1-ijms-20-04757],[@B84-ijms-20-04757]\]. With the exception of Korea, the People's Republic of China, Taiwan, and Japan, limited reports are available on EOAD-associated mutations in Asian countries ([Table 2](#ijms-20-04757-t002){ref-type="table"}). Two *APP* mutations have been identified in patients from Thailand \[[@B12-ijms-20-04757]\] and Iran \[[@B85-ijms-20-04757]\]. Recently, a novel *PSEN1* mutation was reported in a Malaysian family \[[@B70-ijms-20-04757]\]. Our primary goal was to provide clinicians a list of variants that can be accurately used in genetic counseling. Considering our whole cases, this goal is achieved for 9% mutations reported in the Asian population. Limited reports are available regarding EOAD-associated mutations in other East Asian countries. Hence, our investigators have begun efforts for screening AD-related mutations across Asian countries through collaborations. Compared with Caucasian patients, over 30 novel EOAD-associated mutations have been found in the *APP, PSEN1*, and *PSEN2* genes in Asian patients (<http://www.alzforum.org/mutations>). Since the overall population and aging population in most Asian countries is increasing, genetic testing of patients with AD and other types of dementia is important for the diagnosis of dementia.

A limitation of this study is the absence of functional assessment of the possible and probable pathogenic variants, which could simplify their classification \[[@B8-ijms-20-04757]\]. Moreover, only three genes were analyzed. It is possible that de novo mutations in other genes are also involved in the genetic determination of sporadic forms \[[@B16-ijms-20-04757],[@B18-ijms-20-04757],[@B86-ijms-20-04757],[@B87-ijms-20-04757],[@B88-ijms-20-04757],[@B89-ijms-20-04757],[@B90-ijms-20-04757]\]. The limited number of resolved pedigrees and large number of genetically unexplained EOAD patients indicate that additional causal genes remain to be discovered. The next step involves performing whole exome/genome sequencing on negatively screened families and sporadic cases.

In conclusion, among the distinct mutations in the Asian patients and isolated cases in the Asian population, definite pathogenicity accounted for less than 16%, leaving a large group of autosomal dominant pedigrees genetically unexplained. In addition, our findings suggest that continuing the investigation of families harboring known mutations and the elucidation of the missing genetic etiology in unexplained EOAD patients has a vast potential to improve our understanding about the complexity of AD \[[@B1-ijms-20-04757],[@B10-ijms-20-04757],[@B15-ijms-20-04757],[@B90-ijms-20-04757],[@B91-ijms-20-04757]\]. We also suggest that the use of high-throughput sequencing technologies for patients with EOAD and data integration from other -omics analyses (epigenomics, proteomics, transcriptomics, and metabolomics) might help in better understanding the underlying molecular mechanisms of AD.

4. Materials and Methods {#sec4-ijms-20-04757}
========================

Two-hundred patients with EOAD from the University Hospitals of Korea, Malaysia, Thailand, and the Philippines were recruited between 2009 and 2018. All patients underwent a comprehensive clinical examination, including personal medical and family history assessment and neuropsychological assessment. For each patient, AD diagnosis was established using the National Institute of Aging--Alzheimer's Association (NIA--AA) criteria \[[@B92-ijms-20-04757]\]. The project received ethics approval from the Seoul National University College of Medicine of Seoul National Bundang Hospital (SNUH), and written informed consent was obtained from all participants according to the requirements of the Seoul National Bundang Human Research Committee (B-1302/192-006, approval date: 15/03/2013). All procedures involving human participants were conducted in accordance with the ethical standards of the institutional and/or national research committee and 1964 Helsinki Declaration and its later amendments.

4.1. Genetic Analyses {#sec4dot1-ijms-20-04757}
---------------------

Genetic analyses were performed on DNA extracted from whole blood. Sanger sequencing, next-generation sequencing (NGS) and whole exon sequencing (WES) were employed to search for mutations in the *APP, PSEN1*, and *PSEN2* genes in patients with both sporadic and family history of AD. APOE genotypes comprising the APOE ε2, ε3, and ε4 alleles were assayed \[[@B15-ijms-20-04757]\]. To confirm the presence of the identified mutations, standard sequencing was performed in both directions using the previously used primer set \[[@B1-ijms-20-04757],[@B2-ijms-20-04757]\]. Prior to sequencing, PCR products were purified using the GeneAll PCR protocol kit (Seoul, Korea), following the manufacturer's protocol. Big Dye Terminator Cyclic sequencing was performed on an ABI 3730XL DNA Analyzer (<http://eng.bioneer.com/home.aspx>, Bioneer Inc., Dajeon, Korea). The sequenced product was aligned using the NCBI Blast tool (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>), and chromatograms were screened using the DNA BASER (<http://www.dnabaser.com>). Mutations and sequence variants were identified from the NCBI Gene (<http://www.ncbi.nlm.nih.gov/gene>) and UniProt (<http://www.uniprot.org>) databases. Briefly, patients with EOAD were analyzed by high-throughput sequencing, following the schematic diagram shown in [Figure 5](#ijms-20-04757-f005){ref-type="fig"}.

4.2. Bioinformatics {#sec4dot2-ijms-20-04757}
-------------------

To determine whether *APP, PSEN1,* and *PSEN2* variants presented rare or common polymorphisms, the variants were checked in the Korean Genome Reference Database (<http://152.99.75.168/KRGDB/menuPages/firstInfo.jsp>) for their novelty. The full genome sequences of 622 asymptomatic individuals were obtained by whole genome sequencing. In addition, variants were also checked in other large-scale genome reference databases, including the 1000 Genomes (<http://www.internationalgenome.org/>) and Exome Aggregation Consortium (ExAC; <http://exac.broadinstitute.org>) databases. Polymorphism phenotype v2 (PolyPhen-2) and Sorting Intolerant From Tolerant (SIFT) were used to predict whether the amino acid change would be disruptive to the encoded protein.
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![Distribution of *APP, PSEN1,* and *PSEN2* mutations in Asian countries. The fastest increase in the number of elderly individuals has been observed in Asian countries with approximately 60% of all patients diagnosed with dementia. The countries from which the gene mutations are reported are shown in purple.](ijms-20-04757-g001){#ijms-20-04757-f001}

![(**a**) Mutated *APP* residues identified in Asian countries are shown in different colors. (**b**) Location of Val669Leu in APP and mutations located near the β-secretase cleavage site. The nearest mutation is the "Swedish APP" mutation. Additional mutations located near the β-secretase cleavage site are the protective Ala673Thr and the pathogenic Ala673Val.](ijms-20-04757-g002){#ijms-20-04757-f002}

![Mutated *PSEN1* residues identified in the Asian countries are shown in different colors. The predicted membrane topology of PSEN1 with the nine transmembrane domains (green shaded boxes) and boundaries between coding exons is shown. TM, transmembrane domain.](ijms-20-04757-g003){#ijms-20-04757-f003}

![Mutated *PSEN2* residues identified in the Asian countries are shown in different colors. The predicted membrane topology of PSEN2 with the nine transmembrane domains (yellow shaded boxes) and boundaries between coding exons are shown. TM, transmembrane domain.](ijms-20-04757-g004){#ijms-20-04757-f004}

![High-throughput sequencing strategy for identifying gene variants in AD patients. The flow chart illustrates the major steps of the working procedure from patient sample analysis to the identification of mutation.](ijms-20-04757-g005){#ijms-20-04757-f005}

ijms-20-04757-t001_Table 1

###### 

*APP, PSEN1,* and *PSEN2* mutations discovered in Asian early-onset Alzheimer's disease (EOAD) patients between 2009 and 2018.

  Gene          Protein Change   Nucleotide Change   Exon    APOE       AOO (Years)   Gender               Family History   Pathogenicity Prediction                  Clinical Significance                     Population                                          
  ------------- ---------------- ------------------- ------- ---------- ------------- -------------------- ---------------- ----------------------------------------- ----------------------------------------- --------------------------------------------------- -----------
  ***APP***     p.Glu145Lys      c.433G \> A         4       ε3/ε3      55            F                    Y                D: 0.932                                  T:0.496                                   Located outside of the amyloid progressing region   Korean
  p.Val225Ala   c.674T \> C      7                   ε3/ε3   65         F             Y                    D: 932           T: 0.496                                                                                                                                
  p.Thr297Met   c.890C \> T      7                   ε3/ε3   60         F             Y                    D: 0.98          D: 0.0                                                                                                                                  
  p.Pro484Ser   c.1450C \> T     11                  ε4/ε4   61         F             Y                    P: 0.765         T: 0.063                                                                                                                                
  p.Val604Met   c.1810C \> T     14                  ε3/ε3   55         M             Y                    B: 0.450         T: 0.095                                  Thai                                                                                          
  p.Val669Leu   c.2005G \> C     17                  ε3/ε3   55         F             Y                    B: 0.017         T: 0.16                                   Novel mutation, may cause EOAD            Korean                                              
  ***PSEN1***   p.Val96Phe       c.286G \> T         4       ε3/ε4      40            M                    Y                D: 1.0                                    T: 0.002                                  Known pathogenic mutation (EOAD)                    Malaysian
  ε3/ε4         40               F                   N                                                                                                                                                                                                              
  p.Thr116Ile   c.335C \> T      5                   ε3/ε3   38         F             Y                    D: 1.00          D: 0                                      Known pathogenic mutation (EOAD)          Korean                                              
  ε3/ε3         41               F                   Y                                                                                                                                                                                                              
  p.Thr119Ile   c.356C \> T      ε3/ε3               64      F          Y             D: 1.00              D: 0             Novel mutation, may be involved in EOAD                                                                                                 
  p.His163Pro   c.488A \> C      4                   ε3/ε3   37         F             Y                    D: 1.00          D: 0                                      Novel mutation, may be involved in EOAD                                                       
  p.Trp165Cys   c.695G \> T      6                   ε3/ε3   53         M             Y                    D: 1.00          D: 0.001                                  Known pathogenic mutation (EOAD)                                                              
  p.Glu184Gly   c.551A \> G      7                   ε3/ε3   37         F             Y                    D: 0.878         D: 0.005                                  Known pathogenic mutation (EOAD)                                                              
  p.Gly209Ala   c.626G \> C      7                   ε3/ε3   54         F             Y                    D: 1.00          D: 0                                      Novel mutation, may be involved in EOAD                                                       
  p.Leu226Phe   CTC \> TTC       7                   ε3/ε3   37         F             Y                    D: 1.00          D: 0                                      Known pathogenic mutation (EOAD)                                                              
  p.Leu232Pro   c.695T \> C      7                   ε3/ε3   37         M             Y                    D: 1.00          D: 0                                      Novel mutation, may be involved in EOAD                                                       
  p.Glu280Lys   c.826G \> A      8                   ε3/ε3   48         M             Y                    D: 1.00          D: 0                                      Novel mutation, may be involved in EOAD   Malaysian                                           
  ε3/ε3         55               F                   Y                                                                                                                                                                                                              
  ε3/ε3         57               M                   Y                                                                                                                                                                                                              
  p.Ala285Val   c.854C \> T      8                   ε3/ε3   46         F             N                    D: 1.0           D: 0.015                                  Known pathogenic mutation (EOAD)          Korean                                              
  p.Gly417Ala   c.1250G \> C     12                  ε3/ε3   37         M             N                    D: 1.00          D: 0                                      Novel mutation, may be involved in EOAD                                                       
  ***PSEN2***   p.Arg62Cys       c.184C \> T         5       ε3/ε3      49            M                    N                D: 0.877                                  D: 0.05                                   Known mutation, may be involved AD                  Korean
  p.His169Asn   c.505C \> A      6                   ε3/ε3   56         F             Y                    D: 1.00          D: 0                                      Known mutation, May be involved AD                                                            
  p.Val214Leu   c.640G \> A      7                   ε3/ε3   56         M             Y                    D: 0.836         D: 0.09                                   May be involved AD                                                                            
  ε3/ε4         70               F                   Y       D: 0.836   D: 0.09       May be involved AD                                                                                                                                                            

Abbreviations: MC, number of mutations carriers in the family; AOO, age of onset ranges in the family; DD, disease duration (at death or last examination); APOE, apolipoprotein E genotype; F, familial; S, sporadic; Y, yes, U, unknown; D, damaging; AD, Alzheimer's disease; EOAD: early-onset Alzheimer's disease.
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The spectrum of *APP, PSEN1*, and *PSEN2* mutations found in Asian countries.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene                                                                                                           Exon            Codon, Mutation                                                                                                Location in the Protein                                                                                                                 Age of Onset, Clinical Characteristics                                                                                             Pathogenic Nature                                               Country                                          References
  -------------------------------------------------------------------------------------------------------------- --------------- -------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------ --------------------------------------------------
  ***APP***                                                                                                      3               p.Glu145Lys                                                                                                    N-terminal                                                                                                                              50s/Familial, EOAD                                                                                                                 Located outside of the amyloid progressing region               Korea                                            This study

  4                                                                                                              p.Val225Ala     N-terminal                                                                                                     65/Familial, EOAD                                                                                                                       This study                                                                                                                                                                                                                                          

  7                                                                                                              pThr297Met      N-terminal                                                                                                     60s/Familial, EOAD                                                                                                                      This study                                                                                                                                                                                                                                          

  8                                                                                                              p\. Pro484Ser   N-terminal                                                                                                     60s/Familial, EOAD                                                                                                                      This study                                                                                                                                                                                                                                          

  14                                                                                                             p.Val604Met     N-terminal                                                                                                     55/Familial, EOAD                                                                                                                       Pathogenic                                                                                                                         Thailand                                                        This study                                       

  16                                                                                                             p.Val669Leu     N-terminal                                                                                                     56 years; AD with a positive family history                                                                                             Located nearby the β-secretase cleavage site of APP, right next to the Swedish APP (Lys, Met670/671Asn, Leu) mutation              Korea                                                           This study                                       

  p.Asp678Asn                                                                                                    N-terminal      59--65 years/familial, EOAD                                                                                    Probably pathogenic, may enhance the toxic amyloid oligomer formation                                                                   Japan                                                                                                                              Wakutani et al., 2004 \[[@B25-ijms-20-04757]\]                                                                   

  17                                                                                                             p.Glu693del     N-terminal                                                                                                     44 years/familial, EOAD/MCI                                                                                                             Enhances the toxic amyloid oligomer formation                                                                                      Japan                                                           Tomiyama et al., 2008 \[[@B26-ijms-20-04757]\]   

  p\. Val710Gly                                                                                                  TM-I            65--82 years/Familial, AD, Parkinsonism                                                                        Probably pathogenic                                                                                                                     China, Taiwan                                                                                                                      Thajeb et al. 2009 \[[@B27-ijms-20-04757]\]                                                                      

  p\. Thr714Ala                                                                                                  TM-I            47--55 years/Familial, EOAD, epilepsy                                                                          Probably pathogenic                                                                                                                     Iran                                                                                                                               Pasalar et al. 2002 \[[@B28-ijms-20-04757]\]                                                                     

  p.Val715Met                                                                                                    TM-I            41 years/\                                                                                                     Expressed in HEK293 cells, revealed 2\* decrease in Abeta 40 levels. Might destroy the cleavage of gamma secretase at site at Abeta40   Korea                                                                                                                              Park et al., 2008 \[[@B29-ijms-20-04757]\]                                                                       
                                                                                                                                 Familial EOAD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  p.Val717Ile                                                                                                    TM-I            53 years/Familial, EOAD                                                                                        Increased Abeta42/Abeta40 ratio in CHO and HEK293 cells                                                                                 Japan                                                                                                                              Yoshioka et al., 1991 \[[@B30-ijms-20-04757]\]                                                                   

  54 years/unknown, EOAD                                                                                         Thailand        Jiao et al., 2014 \[[@B31-ijms-20-04757]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  p\. Ile718Leu                                                                                                  TM-I            65--82 years/Familial, AD, Parkinsonism                                                                        Probably pathogenic                                                                                                                     China, Taiwan                                                                                                                      Thajeb et al., 2009 \[[@B27-ijms-20-04757]\]                                                                     

  p.Leu720Ser                                                                                                    TM-I            65--82 years/Familial, AD, Parkinsonism                                                                        Probably pathogenic                                                                                                                     China, Taiwan                                                                                                                      Thajeb et al. 2009 \[[@B27-ijms-20-04757]\]                                                                      

  4                                                                                                              p.Leu85Pro      TM-I                                                                                                           26 years, Juvenile EOAD                                                                                                                 Abeta42/Abeta40 ratio increased in HEK293                                                                                          Japan                                                           Ataka et al. 2004 \[[@B54-ijms-20-04757]\]       

  p\. Val96Phe                                                                                                   TM-I            EOAD, 49--60 years                                                                                             2.1 \* increased Abeta 42/40 ratio in COS-1 cells                                                                                       Japan                                                                                                                              Kamino et al. 1996 \[[@B32-ijms-20-04757]\]                                                                      

  p.Val97Leu                                                                                                     TM-I            EOAD                                                                                                           Higher beta secretase activity in human neuroblastoma cells                                                                             China                                                                                                                              Fang et al. 2006 \[[@B33-ijms-20-04757]\]                                                                        

  p\. Phe105Cys                                                                                                  HL-I            59 years/Familial, EOAD                                                                                        Survival of mutant neuroblastoma cells dropped                                                                                          China                                                                                                                              Jiao et al., 2014 \[[@B31-ijms-20-04757]\]                                                                       

  5                                                                                                              p\. Gly111Val   HL-I                                                                                                           EOAD; 59 years/Familial                                                                                                                 Increased ratios of secreted Aβ42/Aβ40 in vitro study                                                                              China                                                           Qiu et al., 2019 \[[@B53-ijms-20-04757]\]        

  p\. Thr116Ile                                                                                                  HL-I            Late 30s--early-40s years; EOAD with a probable familial                                                       Possible pathogenic mechanisms of mutation                                                                                              Korea                                                                                                                              This study                                                                                                       

  p\. Thr119Ile                                                                                                  HL-I            49--64 years; EOAD with a probable familial                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  p.Glu120Lys                                                                                                    HL-I            40--65 years/Familial, EOAD                                                                                    Probably pathogenic                                                                                                                     Iran                                                                                                                               Akbari et al., 2013 \[[@B34-ijms-20-04757]\]                                                                     

  p.Glu123Lys                                                                                                    HL-I            26--45 years, EOAD, myoclonus, epilepsy                                                                        Abeta42/total Abeta increased in COS-1 cells (2.7 \*) and in HEK293 (4 \*) cells                                                        Japan                                                                                                                              Yasuda et al. 1999 \[[@B35-ijms-20-04757]\]                                                                      

  p.Ala136Gly                                                                                                    TM-II           Unknown, EOAD                                                                                                  Survival of mutant neuroblastoma cells dropped, deleterious effects                                                                     China                                                                                                                              Fang et al., 2007 \[[@B36-ijms-20-04757]\]                                                                       

  p.Met139Ile                                                                                                    TM-II           38 years/Familial, EOAD                                                                                        Ratio of Abeta42/total Abeta increased in COS-1 cell lines.                                                                             Korea                                                                                                                              Kim et al., 2010 \[[@B37-ijms-20-04757]\]                                                                        

  p\. Ile143Thr                                                                                                  TM-II           26--45 years, EOAD, myoclonus, epilepsy                                                                        Abeta42/total Abeta increased in COS-1 cells (2.7 \*) and in HEK293 (4 \*) cells                                                        Japan                                                                                                                              Arai et al., 2008 \[[@B38-ijms-20-04757]\]                                                                       

  p.Tyr154Asn                                                                                                    TM-II           40--60 years, EOAD, spastic paraparesis                                                                        Pathogenic nature might be associated with the missing aromatic ring.                                                                   Japan                                                                                                                              Hattori et al., 2004 \[[@B47-ijms-20-04757]\]                                                                    

  6                                                                                                              p.His163Arg     HL-II                                                                                                          43--50 years/5 Japanese families, both familial and de novo cases                                                                       Abeta42/Abeta40 ratio increased 2 \* in COS1 cell lines                                                                            Japan                                                           Kamino et al., 1996 \[[@B32-ijms-20-04757]\]     

  p.His163Arg                                                                                                    HL-II           43--50 years/5 Japanese families, both familial and de novo cases                                              Abeta42/Abeta40 ratio increased 2 \* in COS1 cell lines                                                                                 Korea                                                                                                                              Hong et al., 1997 \[[@B48-ijms-20-04757]\]                                                                       

  p.His163Pro                                                                                                    HL-II           35 years/de novo EOAD, parkinsonism                                                                            The rigid proline might result abnormalities in the border of HL-II and TM-III                                                          Korea                                                                                                                              This study                                                                                                       

  p.Trp165Gly                                                                                                    TM-III          34--38 years; EOAD with strong familiar                                                                        The small glycine is a rare amino acid in the helix                                                                                     Japan                                                                                                                              Higuchi et al., 2000 \[[@B55-ijms-20-04757]\]                                                                    

  p.Trp165Cys                                                                                                    TM-III          55 years; memory decline, followed by difficulty in finding ways and had a strong family history of dementia   Increased Aβ42 and decreased Aβ40 production in vitro; elevated Aβ42/Aβ40 ratio                                                         Korea                                                                                                                              This study                                                                                                       

  45 years; EOAD, a severe form of the illness, with cerebral and cerebellar atrophies and rapid deterioration   India           Syama et al., 2018 \[[@B49-ijms-20-04757]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  p.Ile167del                                                                                                    TM-III          38 years/familial; EOAD, spastic paraparesis                                                                   Deletion might result abnormal conformation in TM-III                                                                                   China                                                                                                                              Jiao et al., 2014 \[[@B31-ijms-20-04757]\]                                                                       

  p.Ser169del                                                                                                    TM-III          EOAD, 42--50 years/familial                                                                                    Missing --OH group might result a missing H-bound in the TM-III                                                                         China                                                                                                                              Guo et al., 2010 \[[@B43-ijms-20-04757]\]                                                                        

  p.Leu173Phe                                                                                                    TM-III          47--50/familial; EOAD with parkinsonism                                                                        Elevated Abeta42 levels and Abeta42/Abeta40 ration in neuroblastoma cells                                                               Japan                                                                                                                              Kasuga et al. 2009 \[[@B50-ijms-20-04757]\]                                                                      

  7                                                                                                              p.Glu184Asp     HL-III                                                                                                         40s years; EOAD, DLB-like phenotype                                                                                                     The smaller asparatic acid might change the loop conformation                                                                      Japan                                                           Yasuda et al. 1997 \[[@B35-ijms-20-04757]\]      

  p.Glu184Gly                                                                                                    HL-III          40s years; probable autosomal dominant EOAD, frontal variant form                                              Resulting potential functional alterations; may also disturb the splicing near exon 7                                                   Thailand                                                                                                                           This study                                                                                                       

  p.Gly206Ser                                                                                                    TM-IV           30--35 years/familial, EOAD                                                                                    Probably pathogenic                                                                                                                     Korea                                                                                                                              Park et al., 2008 \[[@B29-ijms-20-04757]\]                                                                       

  p.Gly209Arg                                                                                                    TM-IV           46--53 years, EOAD                                                                                             Arginine might result extra stress inside the helix and form abnormal hydrogen bonds                                                    Japan                                                                                                                              Sugiyama et al., 1999 \[[@B44-ijms-20-04757]\]                                                                   

  p.Gly209Ala                                                                                                    TM-IV           54 years; MCI with depression, followed by progressive deterioration in verbal and visual memory               The extra --CH3 group in alanine might result extra stress inside the TM-IV region                                                      Korea                                                                                                                              This study                                                                                                       

  p.Ile213Thr                                                                                                    TM-IV           42--47 years, EOAD                                                                                             Increased (1.7 \* Abeta)                                                                                                                Japan                                                                                                                              Kamino et al., 1996 \[[@B32-ijms-20-04757]\]                                                                     

  p.Gly217Asp                                                                                                    HL-IV           42--47 years/familial, EOAD                                                                                    Increased (1.7 \* Abeta)                                                                                                                Japan                                                                                                                              Takao et al., 2002 \[[@B52-ijms-20-04757]\]                                                                      

  p.Leu226Phe                                                                                                    TM-V            37 years; de novo, Aβ plaques observed                                                                         Results elevated Abeta42/Abeta40 ratio in HEK293 cells                                                                                  Korea                                                                                                                              This study                                                                                                       

  p.Leu226Arg                                                                                                    TM-V            60 years/familial, EOAD                                                                                        Probably pathogenic                                                                                                                     China                                                                                                                              Ma et al., 2019 \[[@B41-ijms-20-04757]\]                                                                         

  p.Glu311Arg                                                                                                    TM-V            \> 65 years, familial, LOAD                                                                                    Overproducing toxic Aβ species and enhancing tau phosphorylation                                                                        China                                                                                                                              Dong et al., 2017 \[[@B56-ijms-20-04757]\]                                                                       

  p.Leu232Pro                                                                                                    TM-V            37 years/familial; EOAD                                                                                        The rigid proline might result serious torsion in the TM-V since proline is helix breaker                                               Korea                                                                                                                              This study                                                                                                       

  p.Met233Thr                                                                                                    TM-V            34 years/de novo, EOAD, rapid progressive memory impairment                                                    Elevated (3.2 \*) Abeta42/Abeta40 levels in CHO cells                                                                                   Korea                                                                                                                              Park HK et al., 2008 \[[@B29-ijms-20-04757]\]                                                                    

  p.Phe237Ile                                                                                                    TM-V            35 years/de novo, EOAD, spastic paraparesis                                                                    Probably pathogenic                                                                                                                     Japan                                                                                                                              Sodeyama et al. 2001 \[[@B57-ijms-20-04757]\]                                                                    

  p.Leu248Pro                                                                                                    TM-VI           42 years/familial, EOAD                                                                                        Proline is a helix breaker, resulting in torsion in TM-IV                                                                               China                                                                                                                              Jiao et al., 2014 \[[@B31-ijms-20-04757]\]                                                                       

  p.Leu250Val                                                                                                    TM-VI           40--51 years/Familial, EOAD, myoclonus, seizures                                                               Probably pathogenic                                                                                                                     Japan                                                                                                                              Furuya t al., 2003 \[[@B58-ijms-20-04757]\]                                                                      

  8                                                                                                              p.Ala260Val     TM-VI                                                                                                          27--46 years/Familial, EOAD, Pick inclusions                                                                                            1.5 \* Increased Abeta42/total Abeta in COS1 cells                                                                                 Japan                                                           Ikeda et al., 1996 \[[@B59-ijms-20-04757]\]      

  p.Gly266Ser                                                                                                    HL-VI(a)        35--44 years, EOAD, spastic paraparesis, aphasia                                                               Probably pathogenic                                                                                                                     Japan                                                                                                                              Matsubara-Tsutsui et al., 2002 \[[@B60-ijms-20-04757]\]                                                          

  p.Arg 269His                                                                                                   HL-VI(a)        46--67 years/Familial, EOAD, myoclonus                                                                         Unknown                                                                                                                                 Japan                                                                                                                              Kamimura el al., 1998 \[[@B61-ijms-20-04757]\]                                                                   

  p.Glu273Ala                                                                                                    HL-VI(a)        46--67 years/Familial, EOAD, myoclonus                                                                         Unknown                                                                                                                                 Japan                                                                                                                              Kamimura el al., 1998 \[[@B61-ijms-20-04757]\]                                                                   

  p.Glu280Ala                                                                                                    HL-VI (MA)      48--57 years/Familial, EOAD, parkinsonism                                                                      Probably pathogenic                                                                                                                     Japan                                                                                                                              Tanahashi et al., 1996 \[[@B62-ijms-20-04757]\]                                                                  

  p.Glu280Lys                                                                                                    HL-VI (MA)      48--57; EOAD                                                                                                   Probably pathogenic                                                                                                                     Malaysia                                                                                                                           This study                                                                                                       

  p.Leu282Phe                                                                                                    HL-VI (MA)      51 years, familial, EOAD                                                                                       Probably pathogenic                                                                                                                     Japan                                                                                                                              Hamaguchi et al., 2009 \[[@B63-ijms-20-04757]\]                                                                  

  p.Pro284Leu                                                                                                    HL-VI (MA)      32 years, cotton-wool plaques and neurofibrillary tangles or amyloid angiopathy in brain                       Probably pathogenic                                                                                                                     Japan                                                                                                                              Tabira et al., 2002 \[[@B64-ijms-20-04757]\]                                                                     

  p.Ala285Val                                                                                                    HL-VI (MA)      46 year/de novo, EOAD                                                                                          The Abeta42/total Abeta ratio increased; Abeta40/total Abeta and Abeta38/total Abeta ratios decreased                                   Korea                                                                                                                              This study                                                                                                       

  50.5 years, two families                                                                                       Japan           Ikeuchi et al., 2008 \[[@B65-ijms-20-04757]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  p.Leu286Val                                                                                                    HL-VI (MA)      47 years                                                                                                       Increases in the Abeta42/total Abeta ratio (1.5 \*) and Abeta42/Abeta40 ratio (2.1 \*)                                                  Japan                                                                                                                              Ikeuchi et al., 2008 \[[@B65-ijms-20-04757]\]                                                                    

  Intron 8                                                                                                       Exon9 del       \-                                                                                                             47.5 years, in EOAD with spastic paraparesis                                                                                            elevated Abeta42 levels and Abeta42/40 ratio were observed                                                                         Japan                                                           Tabira et al., 2002 \[[@B64-ijms-20-04757]\]     

                                                                                                                 10              p.Arg352Cys                                                                                                    HL-VI (b)                                                                                                                               56--62 years, EOAD, psychiatric, behavioral symptoms                                                                               Cysteine could result intramolecular disulfide bound            China                                            Jiang et al., 2015 \[[@B66-ijms-20-04757]\]

  11                                                                                                             p.Gly378Glu     TM-VII                                                                                                         37 years, EOAD, familiar positive                                                                                                       Abeta42/Abeta40 ratio increased (3.2 \*)                                                                                           Japan                                                           Ikeda et al., 1996 \[[@B59-ijms-20-04757]\]      

  p.Leu381Val                                                                                                    TM-VII          30s years, AD and spastic paraparesis                                                                          Abeta42/Abeta40 ratio increased (1.9 \*)                                                                                                Japan                                                                                                                              Ikeuchi et al., 2008 \[[@B65-ijms-20-04757]\]                                                                    

  p.Gly384Ala                                                                                                    TM-VII          31--37 years, EOAD, senile plaques and tangles inside proband's brain                                          Beta40 and the Abeta42/Abeta40 ratio decreased and increased significantly. Abeta42/total Abeta ratio increased (3.8 \*)                Japan                                                                                                                              Kamimura et al. 1998 \[[@B61-ijms-20-04757]\]                                                                    

  p.Leu392Val                                                                                                    TM-VII          42 years, EOAD                                                                                                 Abeta42/Abeta40 ratio (2.4\*). An increase in the Abeta42/Abeta40 ratio (2.9 \*)                                                        Japan                                                                                                                              Ikeuchi et al. 2008 \[[@B65-ijms-20-04757]\]                                                                     

  p.Asn405Ser                                                                                                    HL-VII          EOAD, the patient has several senile plaques and tangles in the brain                                          It caused disturbances in the motor neuronal systems, leading to spastic paraparesis                                                    Japan                                                                                                                              Yasuda et al., 2000 \[[@B46-ijms-20-04757]\]                                                                     

  p.Gly417Ala                                                                                                    HL-VIII         37 years; EOAD, parkinsonism, positive familiar                                                                Pathogenic mechanism                                                                                                                    Korea                                                                                                                              This study                                                                                                       

                                                                                                                 12              p.Ala431Val                                                                                                    HL-VIII                                                                                                                                 16 months, t-tau and phospho-Tau levels increased in the CSF, and metabolic deficits were detected in several parts of the brain   Possibly pathogenic                                             Japan                                            Matsushita et al., 2002 \[[@B45-ijms-20-04757]\]

  p.Ala434Thr                                                                                                    HL-VIII         38 years, EOAD,\                                                                                               Threonine might result extramolecular or intramolecular hydrogen bound                                                                  China                                                                                                                              Jiao et al., 2014 \[[@B31-ijms-20-04757]\]                                                                       
                                                                                                                                 Hallucinations, delusions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  p.Thr440del                                                                                                    HL-VIII         52 years, strong familiar history, EOAD and parkinsonism                                                       Probably pathogenic, may alter the normal amyloid production                                                                            Japan                                                                                                                              Ishikawa et al., 2005 \[[@B42-ijms-20-04757]\]                                                                   

  ***PSEN2***                                                                                                    4               p.Arg62Cys                                                                                                     N-term                                                                                                                                  49 years, EOAD                                                                                                                     Possibly pathogenic, may alter the normal amyloid production.   Korea                                            This study

  40--65 years, EOAD                                                                                             Iran            Akbari et al., 2013 \[[@B34-ijms-20-04757]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  5                                                                                                              p.Asn141Tyr     TM-II                                                                                                          43--49 years, EOAD                                                                                                                      No functional data                                                                                                                 China                                                           Niu et al., 2014 \[[@B39-ijms-20-04757]\]        

  6                                                                                                              p.His169Asn     TM-III                                                                                                         50 years; de novo                                                                                                                       It may result in major helix torsion due to histidine to asparagine substitution                                                   Korea                                                           This study                                       

  62 years; AD, de novo                                                                                          China           Shi Z et al., 2015 \[[@B40-ijms-20-04757]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  68 years; FTD, progressive nonfluent aphasia, Familial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  63 years/Familial, LOAD                                                                                        China           Ma et al., 2018 \[[@B41-ijms-20-04757]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  7                                                                                                              p.Val214Leu     TM-IV                                                                                                          56--70 years; AD                                                                                                                        The extra CH3 group in leucine could result extra stress in the TM-IV region                                                       Korea                                                           This study                                       
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviation: APP, amyloid precursor protein; PSEN1, presenilin-1; PSEN2, presenilin-2; AD, Alzheimer's disease; EOAD, early-onset Alzheimer's disease; LOAD, late-onset Alzheimer's disease; MCI, mild cognitive impairment; DLB, dementia with Lewy bodies; FTD, frontotemporal dementia; HEK293, human embryonic kidney 293; CHO, Chinese hamster ovary; COS-1, cercopithecus aethiops kidney; TM, transmembrane domain; **\*** multiplication sign.
